News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1–36
Matches
59
Sources here
1
Companies here
1
Search results Stored financial headlines

Active search

59 matching headlines

Ticker or company: MRCK34Main companies and provider mentions
Clear
Latest

finance.yahoo.com Analyst action

Morgan Stanley Revamps Merck Stock Target After Cancer Breakthrough

This article first appeared on GuruFocus. Merck (NYSE:MRK) slipped Thursday as Wall Street split sharply over what its latest cancer-vaccine breakthrough means for the stock. Morgan Stanley upgraded Merck to Overweight and more than doubled its price target, arguing the company is better positioned to navigate Keytruda's 2028 patent cliff, while RBC Capital Markets downgraded the shares on …

Main company 🇧🇷 Brazil
Read at finance.yahoo.com
Sharemaestro market context Trend signal active 52 weeks +75.2% MRCK34 stored weekly price path from 29 Aug 2025 to 21 Aug 2026
Just inNext headlines
finance.yahoo.com Macro sensitivity Main company 🇧🇷 Brazil

Moderna, Merck, La-Z-Boy, SK Hynix, and More Stocks That Explain Today’s Market

Stock markets are waited on minutes of the Fed's most recent monetary policy meeting for any clues about the forward path on interest rates. Continue Reading

MRCK34 main company
Sharemaestro market context Trend signal active 52 weeks +75.2% MRCK34 stored weekly price path from 29 Aug 2025 to 21 Aug 2026
finance.yahoo.com Market update Main company 🇧🇷 Brazil

Moderna Stock Surges 60%, Merck Rises 6%. At Last, a Successful Cancer Vaccine.

A successful cancer vaccine would be an important new market for Moderna, whose investors have been impatient for it to expand beyond its Covid prevention vaccine. Continue Reading

MRCK34 main company
Sharemaestro market context Trend signal active 52 weeks +75.2% MRCK34 stored weekly price path from 29 Aug 2025 to 21 Aug 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

finance.yahoo.com Analyst action Main company 🇧🇷 Brazil

Merck (MRK) Stock Fair Value Edges Higher After Analysts Back Pipeline Progress

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Price target commentary for Merck has shifted toward a US$140 to US$155 range, anchored by a modest uplift in fair value from US$132.78 to …

MRCK34 main company
Sharemaestro market context Trend signal active 52 weeks +75.2% MRCK34 stored weekly price path from 29 Aug 2025 to 21 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇧🇷 Brazil

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index up 0.2% and t PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already …

MRCK34 mentioned
Sharemaestro market context Trend signal active 52 weeks +75.2% MRCK34 stored weekly price path from 29 Aug 2025 to 21 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇧🇷 Brazil

Is BMY's Growth Portfolio Strong Enough to Offset Legacy Drug Declines?

Bristol Myers Squibb BMY is navigating a revenue mix shift as growth products portfolio now assumes a larger role in the business, helping mitigate the impact of declining sales from mature products facing generics. The growth portfolio — including Opdivo, Opdivo Qvantig, Orencia, Yervoy, …

MRCK34 mentioned
Sharemaestro market context Trend signal active 52 weeks +75.2% MRCK34 stored weekly price path from 29 Aug 2025 to 21 Aug 2026
finance.yahoo.com Market update Main company 🇧🇷 Brazil

Merck (MRK) Wins FDA And EMA Review For Broader RSV Use In Children

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Merck (NYSE:MRK) said the FDA and EMA have accepted supplemental applications to expand ENFLONSIA for preventing RSV in young children at elevated risk. …

MRCK34 main company
Sharemaestro market context Trend signal active 52 weeks +75.2% MRCK34 stored weekly price path from 29 Aug 2025 to 21 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇧🇷 Brazil

MRK Stock Up 5.6% in a Month as Estimates Fall: Buy, Hold or Sell?

Merck's MRK stock is up 5.6% in a month. The key reason for the increase was the strong second-quarter 2026 performance. Merck beat estimates for both earnings and sales in the second quarter. Revenues in the second quarter increased 5% to $16.61 billion as …

MRCK34 mentioned
Sharemaestro market context Trend signal active 52 weeks +75.2% MRCK34 stored weekly price path from 29 Aug 2025 to 21 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇧🇷 Brazil

The Galien Foundation Announces 2026 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Product," and "Best Product for Rare/Orphan Diseases"

A Milestone 20th Anniversary Edition Recognizing Excellence in Medical Science and Patient Care NEW YORK, Aug. 11, 2026 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the nominees for the 2026 Prix Galien USA …

MRCK34 mentioned
Sharemaestro market context Trend signal active 52 weeks +75.2% MRCK34 stored weekly price path from 29 Aug 2025 to 21 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇧🇷 Brazil

ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

Suha Jhaveri, Bill Warren and Jim Wassil added to ILiAD Board of Directors; Antony Blanc appointed Chief Business Officer Appointments deepen vaccine development expertise and enhance global commercial and strategic leadership WESTON, Fla., August 11, 2026--(BUSINESS WIRE)--ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage …

MRCK34 mentioned
Sharemaestro market context Trend signal active 52 weeks +75.2% MRCK34 stored weekly price path from 29 Aug 2025 to 21 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇧🇷 Brazil

S&P 500 Companies' Quarterly Earnings Growth Eases Amid Healthcare Drop, Oppenheimer Says

S&P 500 companies' quarterly earnings growth rate eased from a week ago amid a drop in the healthcar PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. …

MRCK34 mentioned
Sharemaestro market context Trend signal active 52 weeks +75.2% MRCK34 stored weekly price path from 29 Aug 2025 to 21 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇧🇷 Brazil

IMCR Jumps 21.2% in 3 Months as Kimmtrak Growth Fuels More Momentum

Immunocore Holdings plc IMCR has gained 21.2% over the past 12 weeks, putting the durability of that advance in focus. Kimmtrak demand and late-stage pipeline progress give investors concrete operating and clinical milestones to watch. The stock's shorter-term gains have been more modest, while …

MRCK34 mentioned
Sharemaestro market context Trend signal active 52 weeks +75.2% MRCK34 stored weekly price path from 29 Aug 2025 to 21 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇧🇷 Brazil

IMCR Q2 Revenues Climb 18.3% as Kimmtrak Demand Helps Offset EPS Miss

Immunocore Holdings plc IMCR posted second-quarter 2026 revenues of $115.9 million, up 18.3% year over year and above the Zacks Consensus Estimate of $114 million. The company's loss of 2 cents per share, however, was wider than the consensus estimate of a loss of …

MRCK34 mentioned
Sharemaestro market context Trend signal active 52 weeks +75.2% MRCK34 stored weekly price path from 29 Aug 2025 to 21 Aug 2026
finance.yahoo.com Market update Provider-linked mention 🇧🇷 Brazil

BMY Rallies 16.2% in Three Months: Buy, Sell or Hold the Stock?

Bristol Myers Squibb Company BMY has delivered a solid performance in recent months. The biotech major's shares have gained 16.2% over the past three months compared with the industry's growth of 6.8%. The stock has also outperformed both the sector and the S&P 500. …

MRCK34 mentioned
Sharemaestro market context Trend signal active 52 weeks +75.2% MRCK34 stored weekly price path from 29 Aug 2025 to 21 Aug 2026
finance.yahoo.com Guidance Main company 🇧🇷 Brazil

Merck (MRK) Could Be 3% Undervalued On Raised Outlook And Key Drug Approvals

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Merck (MRK) is back in focus after a run of product and earnings headlines. …

MRCK34 main company
Sharemaestro market context Trend signal active 52 weeks +75.2% MRCK34 stored weekly price path from 29 Aug 2025 to 21 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

This Biotech Dealmaker — Tied To Merck, Travere — Is In A Profit-Taking Zone

Ligand stock landed in a profit-taking zone Thursday on a strong second-quarter report and an earnings guidance hike. Continue Reading

MRCK34 main company
Sharemaestro market context Trend signal active 52 weeks +75.2% MRCK34 stored weekly price path from 29 Aug 2025 to 21 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Why This Biotech Dealmaker — Tied To Merck, Travere — Charged Higher

Ligand stock bounded out of a profit-taking zone Thursday on a strong second-quarter report and an earnings guidance hike. Continue Reading

MRCK34 main company
Sharemaestro market context Trend signal active 52 weeks +75.2% MRCK34 stored weekly price path from 29 Aug 2025 to 21 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Merck (MRK) Is Considered a Good Investment by Brokers: Is That True?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though? Let's …

MRCK34 main company
Sharemaestro market context Trend signal active 52 weeks +75.2% MRCK34 stored weekly price path from 29 Aug 2025 to 21 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season

EMA also accepts application for the same population for ENFLONSIA based on results from the Phase 3 SMART trial If approved, children under two years of age at increased risk for severe RSV disease will be eligible to receive an additional dose of ENFLONSIA …

MRCK34 main company
Sharemaestro market context Trend signal active 52 weeks +75.2% MRCK34 stored weekly price path from 29 Aug 2025 to 21 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Merck KGaA Q2 adjusted profit rises 9%, hikes FY outlook

Investing.com-- Merck clocked a stronger second-quarter adjusted profit on Tuesday, aided by strong performances in its life science and electronics divisions, with the company also raising its annual profit outlook. Adjusted earnings before interest, tax, depreciation and amortization rose 9.4% year-on-year to 1.6 billion …

MRCK34 main company
Sharemaestro market context Trend signal active 52 weeks +75.2% MRCK34 stored weekly price path from 29 Aug 2025 to 21 Aug 2026
finance.yahoo.com Deals and strategy Main company 🇧🇷 Brazil

Merck (MRK) Is Racing Beyond Keytruda As Its Biggest Patent Cliff Nears

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Merck (NYSE:MRK) is approaching a major patent cliff for cancer drug Keytruda from 2028. The company is increasing acquisitions and partnerships to broaden …

MRCK34 main company
Sharemaestro market context Trend signal active 52 weeks +75.2% MRCK34 stored weekly price path from 29 Aug 2025 to 21 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Health Canada Approves KEYTRUDA® for the treatment of adult patients with muscle invasive bladder cancer who are ineligible for cisplatin containing chemotherapy, in combination with enfortumab vedotin, as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment

KIRKLAND, QC, Aug. 4, 2026 /PRNewswire/ -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that KEYTRUDA® (pembrolizumab for injection), Merck's anti-PD-1 therapy, in combination with enfortumab vedotin, an antibody-drug conjugate (ADC), is approved by Health Canada as …

MRCK34 main company
Sharemaestro market context Trend signal active 52 weeks +75.2% MRCK34 stored weekly price path from 29 Aug 2025 to 21 Aug 2026
finance.yahoo.com Deals and strategy Main company 🇧🇷 Brazil

MRK Q2 Earnings Call Puts Pipeline Progress in Focus

Merck & Co., Inc. MRK used its second-quarter 2026 call to stress faster pipeline progress and launch execution. Management raised the sales outlook even as acquisition charges produced a quarterly loss. The call also focused on LIPFENDRA access, KEYTRUDA's loss-of-exclusivity transition and whether newer …

MRCK34 main company
Sharemaestro market context Trend signal active 52 weeks +75.2% MRCK34 stored weekly price path from 29 Aug 2025 to 21 Aug 2026
finance.yahoo.com Deals and strategy Main company 🇧🇷 Brazil

Merck & Co Inc (MRK) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and ...

This article first appeared on GuruFocus. Total Revenue: $16.6 billion, an increase of 5% (4% excluding foreign exchange). KEYTRUDA Family Sales: Increased 4% to $8.4 billion, driven by uptake in earlier-stage cancers and robust demand from metastatic indications. KEYTRUDA QLEX Sales: $463 million, with …

MRCK34 main company
Sharemaestro market context Trend signal active 52 weeks +75.2% MRCK34 stored weekly price path from 29 Aug 2025 to 21 Aug 2026
finance.yahoo.com Analyst action Main company 🇧🇷 Brazil

Merck's Weekly HIV Treatment Pipeline 'Interesting,' UBS Says

Merck's (MRK) "HIV pipeline" is brewing in the background, as weekly treatment are interesting and s PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already …

MRCK34 main company
Sharemaestro market context Trend signal active 52 weeks +75.2% MRCK34 stored weekly price path from 29 Aug 2025 to 21 Aug 2026
finance.yahoo.com Analyst action Main company 🇧🇷 Brazil

Merck, Pfizer Lift Full-Year Sales Outlooks Following Second-Quarter Beats

Merck (MRK) and Pfizer (PFE) raised their respective full-year sales outlooks on Tuesday, as both ph PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already …

MRCK34 main company
Sharemaestro market context Trend signal active 52 weeks +75.2% MRCK34 stored weekly price path from 29 Aug 2025 to 21 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Compared to Estimates, Merck (MRK) Q2 Earnings: A Look at Key Metrics

Merck (MRK) reported $16.61 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 5.1%. EPS of -$0.13 for the same period compares to $2.13 a year ago. The reported revenue represents a surprise of +1.69% over the Zacks Consensus …

MRCK34 main company
Sharemaestro market context Trend signal active 52 weeks +75.2% MRCK34 stored weekly price path from 29 Aug 2025 to 21 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Merck (MRK) Reports Q2 Loss, Beats Revenue Estimates

Merck (MRK) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to earnings of $2.13 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents …

MRCK34 main company
Sharemaestro market context Trend signal active 52 weeks +75.2% MRCK34 stored weekly price path from 29 Aug 2025 to 21 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Merck shares rise on big Q2 earnings beat, adjusted FY outlook

Investing.com -- Merck reported significantly better-than-expected earnings for the second quarter, while narrowing and raising its full-year revenue outlook. The company posted a loss per share of $0.13 for the quarter, topping the analyst estimate of a loss of $0.27. Revenue came in at …

MRCK34 main company
Sharemaestro market context Trend signal active 52 weeks +75.2% MRCK34 stored weekly price path from 29 Aug 2025 to 21 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

Merck (NYSE:MRK) Posts Better-Than-Expected Sales In Q2 CY2026

Merck (NYSE:MRK) Posts Better-Than-Expected Sales In Q2 CY2026 Global pharmaceutical company Merck (NYSE:MRK) announced better-than-expected revenue in Q2 CY2026, with sales up 5.1% year on year to $16.61 billion. The company expects the full year's revenue to be around $66.8 billion, close to analysts' …

MRCK34 main company
Sharemaestro market context Trend signal active 52 weeks +75.2% MRCK34 stored weekly price path from 29 Aug 2025 to 21 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

The Merck Product That Absolutely Demolished Wall Street's Forecasts

Merck's new injectable version of Keytruda walloped sales expectations Tuesday, packing a $200 million-plus punch vs. Wall Street's forecasts. Continue Reading

MRCK34 main company
Sharemaestro market context Trend signal active 52 weeks +75.2% MRCK34 stored weekly price path from 29 Aug 2025 to 21 Aug 2026
finance.yahoo.com Deals and strategy Main company 🇧🇷 Brazil

Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline

Sales Growth Reflects Continued Strength in Oncology, Including Initial Uptake of KEYTRUDA QLEX, and Animal Health, Plus Contributions From Launches Such as WINREVAIR Financial Highlights Total Worldwide Sales Were $16.6 Billion (5% Growth; 4% Growth ex-FX) KEYTRUDA/KEYTRUDA QLEX1 Sales Were $8.4 Billion (5% Growth; …

MRCK34 main company
Sharemaestro market context Trend signal active 52 weeks +75.2% MRCK34 stored weekly price path from 29 Aug 2025 to 21 Aug 2026
finance.yahoo.com Deals and strategy Main company 🇧🇷 Brazil

Agilent Technologies (A) Expands Its Oncology Diagnostics Reach—Can Growth Keep Up?

Agilent Technologies Inc. (NYSE:A) just extended its diagnostics franchise into one of oncology's toughest corners. On July 23, the company said European regulators had certified its PD-L1 IHC 22C3 pharmDx test, Code SK006, as a companion diagnostic for epithelial ovarian, fallopian tube, and primary …

MRCK34 main company
Sharemaestro market context Trend signal active 52 weeks +75.2% MRCK34 stored weekly price path from 29 Aug 2025 to 21 Aug 2026
finance.yahoo.com Earnings Main company 🇧🇷 Brazil

What To Expect From Merck’s (MRK) Q2 Earnings

What To Expect From Merck's (MRK) Q2 Earnings Global pharmaceutical company Merck (NYSE:MRK) will be announcing earnings results this Tuesday before market hours. Here's what investors should know. Merck beat analysts' revenue expectations last quarter, reporting revenues of $16.29 billion, up 4.9% year on …

MRCK34 main company
Sharemaestro market context Trend signal active 52 weeks +75.2% MRCK34 stored weekly price path from 29 Aug 2025 to 21 Aug 2026
finance.yahoo.com Regulatory and legal Main company 🇧🇷 Brazil

Merck (MRK) Plans Early HIV Pill Licensing Across 129 Countries

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Merck (NYSE:MRK) has outlined a global access plan for its investigational once-monthly oral HIV prevention pill, alimatravir. The company is pursuing early voluntary licensing …

MRCK34 main company
Sharemaestro market context Trend signal active 52 weeks +75.2% MRCK34 stored weekly price path from 29 Aug 2025 to 21 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context